Regulation of the proinflammatory effects of Fas ligand (CD95L)

被引:308
作者
Chen, JJ
Sun, YN
Nabel, GJ
机构
[1] Univ Michigan, Med Ctr, Dept Internal Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Med Ctr, Dept Biol Chem, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA
关键词
D O I
10.1126/science.282.5394.1714
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Fas ligand (CD95L) inhibits T cell function in immune-privileged organs such as the eye and testis, yet in most tissues CD95L expression induces potent inflammatory responses. With a stably transfected colon carcinoma cell Line, CT26-CD95L, the molecular basis for these divergent responses was defined. When injected subcutaneously, rejection of CT26-CD95L was caused by neutrophils activated by CD95L. CT26-CD95L survived in the intraocular space because of the presence of transforming growth factor-beta (TGF-beta), which inhibited neutrophil activation. Providing TGF-beta to subcutaneous sites protected against tumor rejection. Thus, these cytokines together generate a microenvironment that promotes immunologic tolerance, which may aid in the amelioration of allograft rejection.
引用
收藏
页码:1714 / 1717
页数:4
相关论文
共 38 条
[1]   Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts [J].
Allison, J ;
Georgiou, HM ;
Strasser, A ;
Vaux, DL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3943-3947
[2]   Inhibition of the alloantibody response by CD95 ligand [J].
Arai, H ;
Chan, SY ;
Bishop, DK ;
Nabel, GJ .
NATURE MEDICINE, 1997, 3 (08) :843-848
[3]   Gene transfer of Fas ligand induces tumor regression in vivo [J].
Arai, H ;
Gordon, D ;
Nabel, EG ;
Nabel, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) :13862-13867
[4]   ALTERED METABOLIC AND ADHESIVE PROPERTIES AND INCREASED TUMORIGENESIS ASSOCIATED WITH INCREASED EXPRESSION OF TRANSFORMING GROWTH FACTOR-BETA-1 [J].
ARRICK, BA ;
LOPEZ, AR ;
ELFMAN, F ;
EBNER, R ;
DAMSKY, CH ;
DERYNCK, R .
JOURNAL OF CELL BIOLOGY, 1992, 118 (03) :715-726
[5]   A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[6]   Transforming growth factor beta 1 inhibits mitogen-activated protein kinase induced by basic fibroblast growth factor in smooth muscle cells [J].
Berrou, E ;
FontenayRoupie, M ;
Quarck, R ;
McKenzie, FR ;
LevyToledano, S ;
Tobelem, G ;
Bryckaert, M .
BIOCHEMICAL JOURNAL, 1996, 316 :167-173
[7]   CELL-AUTONOMOUS FAS (CD95) FAS-LIGAND INTERACTION MEDIATES ACTIVATION-INDUCED APOPTOSIS IN T-CELL HYBRIDOMAS [J].
BRUNNER, T ;
MOGIL, RJ ;
LAFACE, D ;
YOO, NJ ;
MAHBOUBI, A ;
ECHEVERRI, F ;
MARTIN, SJ ;
FORCE, WR ;
LYNCH, DH ;
WARE, CF ;
GREEN, DR .
NATURE, 1995, 373 (6513) :441-444
[8]  
Chen J., unpublished
[9]   The role of Fas in autoimmune diabetes [J].
Chervonsky, AV ;
Wang, Y ;
Wong, FS ;
Visintin, I ;
Flavell, RA ;
Janeway, CA ;
Matis, LA .
CELL, 1997, 89 (01) :17-24
[10]   TUMOR SECRETION OF GROWTH-FACTORS [J].
DAUGHADAY, WH ;
DEUEL, TF .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1991, 20 (03) :539-563